- All regions
- Asia
Hong Kong
India
Japan
Korea, Republic of
Singapore
Taiwan- Australasia
Australia
New Zealand- Europe
Austria
Belgium
Bosnia Herzegovina
Bulgaria
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Macedonia
Netherlands
Norway
Poland
Portugal
Romania
Serbia Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
United Kingdom- North America
Canada
United States
Top Pharmaceuticals stocks in United States
Manufacturers and marketers of generic and specialty drugs, as well as researchers and developers of new drugs, medical products and procedures.
| Name | Market Cap | Price to Earnings TTM | Dividend Yield % TTM |
|---|---|---|---|
 LLYEli Lilly and Co | $751.56bn | 43.16 | 0.68% |
| JNJ WDJohnson & Johnson | $397.54bn | 20.6 | 2.81% |
| JNJJohnson & Johnson | $377.51bn | 19.24 | 3.16% |
| ABBVAbbvie | $339.94bn | 32.11 | 3.27% |
| MRKMerck & Co | $209.32bn | 9.35 | 3.79% |
| AMGNAmgen | $158.77bn | 23.58 | 3.09% |
| PFEPfizer | $145.83bn | 11.26 | 6.59% |
| GILDGilead Sciences | $136.38bn | 15.95 | 2.83% |
| VRTXVertex Pharmaceuticals | $120.40bn | 31 | n/a |
| CELG RTBristol-Myers Squibb Co | $95.36bn | 0.01 | 6934.1% |
| BMYBristol-Myers Squibb Co | $95.36bn | 11.92 | 5.16% |
| MCKMcKesson | $88.63bn | 24 | 0.37% |
| ZTSZoetis | $68.99bn | 27.77 | 1.16% |
| REGNRegeneron Pharmaceuticals | $61.30bn | 13.75 | n/a |
| ALNYAlnylam Pharmaceuticals | $41.06bn | n/a | n/a |
| CAHCardinal Health | $38.42bn | 23.06 | 1.26% |
| HZNPHorizon Therapeutics | $26.63bn | 51.44 | n/a |
| RPRXRoyalty Pharma | $20.15bn | 14.62 | 2.37% |
| BIIBBiogen | $19.67bn | 11.29 | n/a |
| ITCIIntra-Cellular Therapies | $14.04bn | n/a | n/a |